Result of General Meeting

Summary by AI BETAClose X

CRISM Therapeutics Corporation announced that all resolutions were unanimously passed at its General Meeting, with over 99.97% of votes in favour for both resolutions. This signifies shareholder approval for the company's funding round, which, combined with recent grant finance, positions CRISM Therapeutics strongly to execute its strategy. Admission of 22,500,000 Conditional Placing Shares and 2,450,000 Retail Offer Shares is expected on 16 June 2026, bringing the total issued share capital to 79,185,266 Ordinary Shares. Additionally, 25,000,000 Warrants exercisable at 15 pence have been granted.

Disclaimer*

UK 100

Latest directors dealings